Rapid 90-minute COVID-19 test shown to be highly accurate

Blue circular CovidNudge cartridge inside the NudgeBox analyzer. Credit: Thomas Angus / Imperial College London

The 90-minute COVID-19 examination showed more than 94 percent sensitivity and 100 percent specificity in a new study.

Work published in the magazine Lancet microbe, Was led by scientists at Imperial College London. In research, high-speed tests, which do not require a laboratory and can be performed in small cartridges from a mobile phone, were used on 386 NHS staff and patients.

The lab-in-cartridge rapid testing device, which can be performed on a patient’s bed, was shown to have a greater than 94% sensitivity and 100% specificity, which meant that it had a high degree of accuracy and very little false negatives and no False was not produced. Affirmative.

The test is currently being used successfully in eight London hospitals, and is being rolled out nationally, and data continues to be collected from testing equipment for continuous evaluation. The UK government recently placed an order for 5.8 million test kits.

To perform the test, a pediatric-shaped nose from a patient is inserted into the device, which then looks for traces of genetic material related to the SARS-CoV-2 virus, which causes COVID-19.

A result is available within 90 minutes compared to the traditional COVID-19 test, which results in 24 hours. A test is now being developed to simultaneously assess Flu-A, Flu-B, and RSV as well as COVID 19.

Professor Graham Cook, lead author of the study of the Department of Infectious Diseases at Imperial, said: “These results suggest tests, which can be performed on a patient’s bed, without the need to handle any sample material, for standard testing There is comparable accuracy. Many tests involve a trade-off between speed and accuracy, but this test manages to achieve both. Developing an effective bedside test within three months between teams of engineers, physicians, and virologists There has been an incredible collaboration. ”

The device, manufactured by DnaNudge, an Imperial start-up headquartered in White City, was used on 280 NHS staff members, including suspect COVID-19, 15 patients at A&E, with suspected COVID-19, and 91 hospitalized patients. (Some of which were) not exhibiting COVID-19 symptoms).

Samples from all individuals in the study were analyzed on both rapid-testing devices, COVIDNudge tests and standard hospital laboratory equipment — and then compared the results.

The research team, which included scientists and physicians from Imperial, Imperial College Healthcare NHS Trust, DnaNudge, Chelsea & Westminster Hospital NHS Foundation Trust and Oxford University Hospitals NHS Trust, assessed sensitivity and specificity. Sensitivity is a measure of how well a test produces positive results for those who indicate it and how negative a test will produce. Specificity, on the other hand, is a measure of a test’s ability to produce a negative result for those who do not have the disease, and is indicative of the possibility of false positive results.

The percentage of those found positive for COVID-19 was 18 percent (the study was conducted at the peak of COVID-19). Results showed 67 samples tested positive on the COVIDNudge test, compared to 71 positive results against a range of NHS standard laboratory machines, representing a value of 94 percent sensitivity. This study was supported by the National Health Research Imperial Biomedical Research Center. CEO and co-founder of Denius. Scale, so we explicitly believe that it provides very significant potential in the context of large-scale population testing during the COVID-19 pandemic. The platform is well suited for testing in primary care and community settings with potential for use in non-health care settings such as care homes. , To help bring art back to schools, transportation centers, offices, and theaters and venues. However, further studies of real-world effectiveness in non-clinical sets will require tings before widespread deployment. ”

The research team has recently received a CE mark, enabling its additional use in non-clinical locations (it has previously been approved by the UK Medicine and Healthcare Regulatory Agency).

The team states that each device is Wi-Fi enabled, allowing test results to be safely sent to the hospital’s record system.

Testing for this study took place between 10 April and 12 May at three NHS sites: St Mary’s Hospital, Imperial College Healthcare NHS Trust, London; Chelsea and Westminster Hospital NHS Foundation Trust, London and John Radcliffe Hospital, Oxford University Hospital NHS Foundation Trust, Oxford.

Dr. Said Bob Klaber, director of strategy, research and innovation at Imperial College Healthcare NHS Trust. “As an organization we are focused on using research and innovation for continuous improvement to take care. It has been fantastic to work closely with scientists, practitioners and newcomers from DnaNudge, Imperial College London and the Trust , Along with many of our patients and staff. In order to assess the practicality and validity of this exciting trial, clinicians and their patients need to get accurate results as quickly as possible on how we can safely navigate clinical pathways. And we are very keen to pursue it more widely. ”

Follow the latest news on the outbreak of Coronavirus (COVID-19)

Provided by Imperial College London

Quotes: Rapid 90-minute COVID-19 test shown to be highly accurate (2020, 17 September) from https://medicalxpress.com/news/2020-09-rapid-minute-covid-shown-highs.html 18 September 2020 Retrieve

This document is subject to copyright. Except for any fair working for the purpose of personal study or research, no part may be reproduced without written permission. The content is provided for information purposes only.